search button

Metformin use and young age lung cancer: A case series report

  • Authors:
    • Bo Deng
    • Yi Wang
    • Dong Xie
    • Shawn M. Stoddard
    • Ping Yang

  • View Affiliations

  • Published online on: March 8, 2016     https://doi.org/10.3892/ol.2016.4307
  • Pages: 2899-2902
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Metformin, a widely-prescribed antihyperglycemic drug for the treatment of diabetes mellitus type 2 (DM-II), has been demonstrated to be antineoplastic in vivo and in vitro. However, various preclinical and epidemiological studies investigating the effects of metformin on lung cancer have obtained inconclusive results. The aim of the present study was to retrospectively investigate the effects of metformin, for the treatment of diabetes mellitus type 2 (DM‑II), on the onset of lung cancer. In the present study, the pathological features of ten consecutive young age lung cancer cases, aged between 15 and 45 years old at the time of diagnosis and exhibiting existing primary DM, were investigated using the Mayo Clinic Lung Cancer Cohort database. Amongst this cohort, there were 2 cases of DM type 1 (DM‑I) and 8 cases of DM‑II. Of these patients, two exhibiting adenocarcinoma and DM‑II had not been administered metformin; however, 1 patient exhibiting lymphoma and 4 patients with pulmonary neuroendocrine tumors (NETs) had been administered metformin at least 12 months prior to lung cancer diagnosis. The remaining 3 patients exhibiting NETs and DM‑II had been treated with insulin therapy. The present study hypothesized that the high proportion of NETs observed in the cases of metformin‑treated DM‑II was unlikely to be a random event. It was suggested that metformin treatment was not effective in the prevention of pulmonary NETs, and that metformin may instead induce the occurrence of NETs via as yet unknown signaling pathways. The present hypothesis may potentially serve as a novel indicator for the requirement to monitor young patients with diabetes, who are being treated with metformin, for the occurrence of pulmonary NETs.
View Figures
View References

Related Articles

Journal Cover

April-2016
Volume 11 Issue 4

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 2.9
  • Ranked Oncology
    (total number of cites)
  • CiteScore: 6.3
  • CiteScore Rank: Q2: #119/366 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.725
  • SCImago Journal Rank (SJR): 0.639
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Deng B, Wang Y, Xie D, Stoddard SM and Yang P: Metformin use and young age lung cancer: A case series report. Oncol Lett 11: 2899-2902, 2016
APA
Deng, B., Wang, Y., Xie, D., Stoddard, S.M., & Yang, P. (2016). Metformin use and young age lung cancer: A case series report. Oncology Letters, 11, 2899-2902. https://doi.org/10.3892/ol.2016.4307
MLA
Deng, B., Wang, Y., Xie, D., Stoddard, S. M., Yang, P."Metformin use and young age lung cancer: A case series report". Oncology Letters 11.4 (2016): 2899-2902.
Chicago
Deng, B., Wang, Y., Xie, D., Stoddard, S. M., Yang, P."Metformin use and young age lung cancer: A case series report". Oncology Letters 11, no. 4 (2016): 2899-2902. https://doi.org/10.3892/ol.2016.4307